IL-20, an anti-angiogenic cytokine that inhibits COX-2 expression

被引：35

作者：

Heuzé-Vourc'h, N

Liu, M

Dalwadi, H

Baratelli, FE

Zhu, L

Goodglick, L

Pold, M

Sharma, S

Ramirez, RD

Shay, JW

Minna, JD

Strieter, RM

Dubinett, SM ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90024 USA

[2] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Lung Canc Res Program, Los Angeles, CA USA

[3] Vet Affairs Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA

[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA USA

[5] Univ Texas, SW Med Ctr, Hamon Ctr Therapuet Oncol Res, Dallas, TX USA

[6] Dallas Vet Affairs Med Ctr, Dallas, TX USA

[7] Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX USA

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2005年 / 333卷 / 02期

关键词：

interleukin-20; cyclooxygenase-2; prostaglandin-E-2; lung cancer; angiogenesis; NSCLC; human bronchial epithelial cells;

D O I：

10.1016/j.bbrc.2005.05.122

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

COX-2 overexpression and subsequent PGE(2) production are frequently associated with non-small cell lung cancer and are implicated in tumor-mediated angiogenesis. Here, we report for the first time that IL-20 downregulates COX-2 and PGE(2) in human bronchial epithelial and endothelial cells. Flow cytometry analysis suggests that IL-20-dependent inhibition of COX-2/PGE(2) occurs through the IL-22R1/IL-2OR2 dimers. In addition, we report that IL-20 exerts anti-angiogenic effects, inhibiting experimental angiogenesis. IL-20-mediated inhibition of PMA-induced angiogenesis occurs through the COX-2 regulatory pathway. Altogether our findings revealed that IL-20 is a negative modulator of COX-2/PGE(2) and inhibits angiogenesis. (c) 2005 Elsevier Inc. All rights reserved.

引用

页码：470 / 475

页数：6

共 21 条

[1] Interleukin 20: Discovery, receptor identification, and role in epidermal function [J].

Blumberg, H ;

Conklin, D ;

Xu, WF ;

Grossmann, A ;

Brender, T ;

Carollo, S ;

Eagan, M ;

Foster, D ;

Haldeman, BA ;

Hammond, A ;

Haugen, H ;

Jelinek, L ;

Kelly, JD ;

Madden, K ;

Maurer, MF ;

Parrish-Novak, J ;

Prunkard, D ;

Sexson, S ;

Sprecher, C ;

Waggie, K ;

West, J ;

Whitmore, TE ;

Yao, L ;

Kuechle, MK ;

Dale, BA ;

Chandrasekher, YA .

CELL, 2001, 104 (01) :9-19

[2] Lung cancer and cyclooxygenase-2 [J].

Castelao, JE ;

Bart, RD ;

DiPerna, CA ;

Sievers, EM ;

Bremner, RM .

ANNALS OF THORACIC SURGERY, 2003, 76 (04) :1327-1335

[3] Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention [J].

Chun, KS ;

Surh, YJ .

BIOCHEMICAL PHARMACOLOGY, 2004, 68 (06) :1089-1100

[4] Targeting cyclooxygenase-2 in human neoplasia: Rationale and promise [J].

Dannenberg, AJ ;

Subbaramaiah, K .

CANCER CELL, 2003, 4 (06) :431-436

[5] The contributions of cyclooxygenase-2 to tumor angiogenesis [J].

Gately, S .

CANCER AND METASTASIS REVIEWS, 2000, 19 (1-2) :19-27

[6]

Herschman Harvey R, 2003, Mol Imaging Biol, V5, P286

[7]

Heuze-Vourc'h N, 2003, CANCER RES, V63, P766

[8] Cyclooxygenase-5: a target for the prevention and treatment of breast cancer [J].

Howe, LR ;

Subbaramaiah, K ;

Brown, AMC ;

Dannenberg, AJ .

[9]

Huang M, 1998, CANCER RES, V58, P1208

[10]

HUANG M, 1995, CANCER RES, V55, P3847

← 1 2 3 →